期刊
LEUKEMIA
卷 29, 期 5, 页码 1084-1091出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2015.12
关键词
-
资金
- CEPHALON
- TEVA
In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n = 104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n = 40). The rate of molecular (m) CR was 74% in hematological and 62% in molecular relapse (P = 0.3). All patients with extramedullary relapse (n = 11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n = 93), the 3-year OS was 80% compared with 59% without transplantation (n = 55) (P = 0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration >= 1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P = 0.03, P = 0.01, P = 0.01) and on leukemia-free survival (P = 0.006, P < 0.0001, P = 0.003), respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据